|
KMID : 0366220120470010008
|
|
Korean Journal of Hematology
2012 Volume.47 No. 1 p.8 ~ p.16
|
|
|
Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation
|
|
Erin-Siobhain R. Currin
Ajay K. Gopal
|
|
|
Abstract
|
|
|
|
Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease, to one that is curable in the vast majority of cases. Despite this success, some patients experience relapse. To address this unmet need a variety of agents, classes of drugs, and strategies have demonstrated activity in HL recurring after autologous hematopoietic stem cell transplantation. These include chemotherapeutics (gemcitabine-based combinations, bendamustine), histone deacetylase (HDAC) inhibitors (panobinostat), immunomodulatory agents (lenalidomide), mTOR inhiobitors (everolimus), monoclonal antibodies (rituximab), and antibody-drug conjugates (brentuximab vedotin) as well the potential of long-term disease control via allogeneic transplantation. Such advances reflect our increased understanding of the biology of HL and hold promise for continued improved outcomes for those suffering with this condition.
|
|
|
KEYWORD
|
|
|
Hodgkin lymphoma, Antibody drug conjugates, allogeneic transplant, HDAC inhibitor, IMID, mTOR
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|
|